In a filing, Apellis Pharmaceuticals Inc revealed its Officer Francois Cedric acquired Company’s shares for reported $38168.0 on Jul 15 ’25. In the deal valued at $20.09 per share,1,900 shares were bought.
Then, Francois Cedric bought 137,465 shares, generating $2,774,922 in total proceeds.
Before that, Watson David O. sold 5,000 shares. Apellis Pharmaceuticals Inc shares valued at $93,850 were divested by the General Counsel at a price of $18.77 per share. As a result of the transaction, Watson David O. now holds 133,730 shares, worth roughly $2.59 million.
Raymond James downgraded its Apellis Pharmaceuticals Inc [APLS] rating to an Outperform from a a Strong buy in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering APLS with “an Overweight” recommendation on April 29, 2025. Goldman revised its rating on December 17, 2024. It rated APLS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -2.81% to $19.35. Over the last five days, the stock has gained 8.16%. Apellis Pharmaceuticals Inc shares have fallen nearly -50.24% since the year began. Nevertheless, the stocks have fallen -39.36% over the past one year. While a 52-week high of $42.47 was reached on 01/07/25, a 52-week low of $16.10 was recorded on 05/15/25.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 18.87, which if violated will result in even more drops to 18.40. On the upside, there is a resistance level at 20.08. A further resistance level may holdings at 20.82.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2025-06-13, dropping by -2.11 million shares to a total of 25.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 27.25 million shares. There was a decline of -8.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 21, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $31 price target.
